These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 15210352)
41. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. Yang B; Gao L; Li L; Lu Z; Fan X; Patel CA; Pomerantz RJ; DuBois GC; Zhang H J Biol Chem; 2003 Feb; 278(8):6596-602. PubMed ID: 12480936 [TBL] [Abstract][Full Text] [Related]
42. Comparative analyses of human immunodeficiency virus type 1 (HIV-1) and HIV-2 Vif mutants. Reddy TR; Kraus G; Yamada O; Looney DJ; Suhasini M; Wong-Staal F J Virol; 1995 Jun; 69(6):3549-53. PubMed ID: 7745702 [TBL] [Abstract][Full Text] [Related]
43. Antibody VH domains as small recognition units. Davies J; Riechmann L Biotechnology (N Y); 1995 May; 13(5):475-9. PubMed ID: 9634788 [TBL] [Abstract][Full Text] [Related]
44. Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. Courcoul M; Patience C; Rey F; Blanc D; Harmache A; Sire J; Vigne R; Spire B J Virol; 1995 Apr; 69(4):2068-74. PubMed ID: 7884852 [TBL] [Abstract][Full Text] [Related]
45. Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Auclair JR; Green KM; Shandilya S; Evans JE; Somasundaran M; Schiffer CA Proteins; 2007 Nov; 69(2):270-84. PubMed ID: 17598142 [TBL] [Abstract][Full Text] [Related]
46. Human single-chain antibodies inhibit replication of human immunodeficiency virus type 1 (HIV-1). Liu F; Kumar M; Ma Q; Duval M; Kuhrt D; Junghans R; Posner M; Cavacini L AIDS Res Hum Retroviruses; 2005 Oct; 21(10):876-81. PubMed ID: 16225415 [TBL] [Abstract][Full Text] [Related]
47. Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies. Tanaka T; Lobato MN; Rabbitts TH J Mol Biol; 2003 Aug; 331(5):1109-20. PubMed ID: 12927545 [TBL] [Abstract][Full Text] [Related]
48. Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Davies J; Riechmann L Protein Eng; 1996 Jun; 9(6):531-7. PubMed ID: 8862554 [TBL] [Abstract][Full Text] [Related]
49. Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation. Tanaka T; Rabbitts TH EMBO J; 2003 Mar; 22(5):1025-35. PubMed ID: 12606568 [TBL] [Abstract][Full Text] [Related]
50. Prevalence of anti-vif antibodies in HIV-1 infected individuals assessed using recombinant baculovirus expressed vif protein. O'Neil C; Lee D; Clewley G; Johnson MA; Emery VC J Med Virol; 1997 Mar; 51(3):139-44. PubMed ID: 9139075 [TBL] [Abstract][Full Text] [Related]
51. Development of genetic vaccines for pathogenic genes: construction of attenuated vif DNA immunization cassettes. Ayyavoo V; Nagashunmugam T; Boyer J; Mahalingam S; Fernandes LS; Le P; Lin J; Nguyen C; Chattargoon M; Goedert JJ; Friedman H; Weiner DB AIDS; 1997 Oct; 11(12):1433-44. PubMed ID: 9342065 [TBL] [Abstract][Full Text] [Related]
52. Recombinant rabbit single-chain antibodies bind to the catalytic and C-terminal domains of HIV-1 integrase protein and strongly inhibit HIV-1 replication. da Silva FA; Li M; Rato S; Maia S; Malhó R; Warren K; Harrich D; Craigie R; Barbas C; Goncalves J Biotechnol Appl Biochem; 2012; 59(5):353-66. PubMed ID: 23586912 [TBL] [Abstract][Full Text] [Related]
53. An improved model of association for VH-VL immunoglobulin domains: asymmetries between VH and VL in the packing of some interface residues. Vargas-Madrazo E; Paz-García E J Mol Recognit; 2003; 16(3):113-20. PubMed ID: 12833565 [TBL] [Abstract][Full Text] [Related]
54. Mutational analysis of the human immunodeficiency virus type 1 Vif protein. Simon JH; Sheehy AM; Carpenter EA; Fouchier RA; Malim MH J Virol; 1999 Apr; 73(4):2675-81. PubMed ID: 10074113 [TBL] [Abstract][Full Text] [Related]
55. When accessories turn out to be essential. Trono D Nat Med; 1998 Dec; 4(12):1368-9. PubMed ID: 9846571 [No Abstract] [Full Text] [Related]
56. Blocking HIV-1 Vif restores a natural mechanism of intracellular antiviral defense. Bovolenta C Curr Drug Targets Immune Endocr Metabol Disord; 2004 Dec; 4(4):257-63. PubMed ID: 15578976 [TBL] [Abstract][Full Text] [Related]
57. Construction and characterization of a camelized, human, VH-based peptide vaccine against CD20 antigen. Liu J; Tan Y; Zhang R Immunotherapy; 2013 Feb; 5(2):135-41. PubMed ID: 23413905 [TBL] [Abstract][Full Text] [Related]
58. Subcellular localization of the Vif protein of human immunodeficiency virus type 1. Goncalves J; Jallepalli P; Gabuzda DH J Virol; 1994 Feb; 68(2):704-12. PubMed ID: 8289374 [TBL] [Abstract][Full Text] [Related]
59. Physicochemical improvement of rabbit derived single-domain antibodies by substitutions with amino acids conserved in camelid antibodies. Shinozaki N; Hashimoto R; Noda M; Uchiyama S J Biosci Bioeng; 2018 Jun; 125(6):654-661. PubMed ID: 29398547 [TBL] [Abstract][Full Text] [Related]
60. Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase. Kataropoulou A; Bovolenta C; Belfiore A; Trabatti S; Garbelli A; Porcellini S; Lupo R; Maga G Nucleic Acids Res; 2009 Jun; 37(11):3660-9. PubMed ID: 19369217 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]